Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

PIPE-791

Small molecule · developed by Contineum Therapeutics

Phase 2 Most advanced trial

CTNM Developer

2 Registered trials

What is PIPE-791?

PIPE-791 is an investigational small-molecule drug studied in Idiopathic Pulmonary Fibrosis, Chronic Osteoarthritis Pain, Chronic Low Back Pain.

At a glance

Drug type: Small molecule
Therapy area: Musculoskeletal, Respiratory
Developer: Contineum Therapeutics (CTNM)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07284459	Phase 2	Idiopathic Pulmonary Fibrosis	Recruiting	CTNM
NCT06810245	Phase 1	Chronic Osteoarthritis Pain	Completed	CTNM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Idiopathic Pulmonary FibrosisChronic Low Back PainChronic Osteoarthritis Pain

More from Contineum Therapeutics

PIPE-307 Phase 1 PIPE-505 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the CTNM page.

Follow CTNM, the company behind PIPE-791

See CTNM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CTNM catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z